Oracle Fusion Middleware's Reports Developer is widely used in enterprises; a network-exploitable full-takeover vulnerability can disrupt systems and enable data theft and lateral movement.
CVE-2026-62612
Network-exploitable takeover of Oracle Reports Developer via HTTP (v12.2.1.19.0).
Is CVE-2026-62612 being exploited?
Not confirmed. CVE-2026-62612 does not appear in CISA's Known Exploited Vulnerabilities catalog, which records only exploitation that has been observed and reported publicly. That is evidence of absence of a report, not evidence the flaw is unattacked. EPSS currently estimates a 0.40% probability of exploitation in the next 30 days.
How severe is CVE-2026-62612?
CVE-2026-62612 is rated High with a CVSS score of 8.8. Severity describes how bad exploitation would be, not how likely it is: pair it with exploitation evidence before deciding what to patch first.
Is there a patch for CVE-2026-62612?
Yes. A fix has been recorded for CVE-2026-62612. The vendor advisory is the authority on the exact fixed version — apply it from there rather than from a summary.
What does CVE-2026-62612 affect?
CVE-2026-62612 affects Oracle Reports Developer 12.2.1.19.0, Oracle Fusion Middleware (Security & Authentication component). Confirm the exact affected versions against the vendor advisory before deciding you are exposed.
What should I do about CVE-2026-62612?
Apply vendor patch when released; immediately restrict network access, segment, and monitor logs.
Exploitation status reflects CISA's KEV catalog as we last synced it. Check the catalog directly.
Low-privileged attacker with HTTP access can fully compromise Oracle Reports Developer (High C/I/A), enabling data exfiltration, service disruption, and lateral movement.
Immediate action required
- affected12.2.1.19.0
As published in the CVE Program record. A version outside these ranges is not a statement that it is unaffected — vendors sometimes understate a range, and distribution-backported builds carry upstream numbers that do not reflect what was patched into them.